ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) for ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARA D MOON | — |
Medicare/Medicaid MMM
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare H.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARA D MOON | — |
Alcohol and Drug Abuse ALC
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARA D MOON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.